Letter to Louisiana Senators

Subject: Request for Legislative Investigation into Louisiana Medical Marijuana Pricing and Market Concentration

Dear Senator,

I am writing as a Louisiana resident concerned that the structure of Louisiana’s medical marijuana program is harming everyday patients through excessive prices and limited competition.

The Louisiana Department of Health states that Louisiana has only two licensed medical marijuana manufacturers: Advanced Biomedics LLC d/b/a Ilera Holistic Healthcare and Good Day Farm Louisiana LLC. LDH also states that retailers may sell only marijuana products manufactured by Louisiana-licensed firms, and that retail permits remain limited. This means Louisiana patients are not participating in a meaningfully competitive market. They are purchasing medicine within a tightly restricted state-created system.

I compared publicly listed menu data from Good Day Farm locations in Louisiana and Arkansas. The results raise serious concerns:

• Louisiana 3.5g flower averaged $53.19, compared with $21.50 in Arkansas.
• Louisiana 1g vaporizers averaged $74.10, compared with $42.33 in Arkansas.
• Bossier City 3.5g flower averaged $50.00, compared with $22.50 in Texarkana, Arkansas.
• Bossier City 14g flower averaged $151.33, compared with about $54–$55 in Arkansas comparison data.

These differences suggest that Louisiana patients may be paying dramatically more for comparable medical cannabis products than patients in nearby markets. For many Louisianians, especially disabled patients, veterans, seniors, and people living on fixed incomes, these prices are not sustainable.

I respectfully ask that the Senate investigate whether Louisiana’s medical marijuana framework is producing excessive pricing, inadequate competition, vertical concentration, or barriers to entry that harm patients. At minimum, I ask the Legislature to consider reforms requiring price transparency, wholesale/retail markup reporting, expanded licensing, stronger conflict-of-interest review, and patient affordability protections.

This is not a request to deregulate safety. It is a request to protect patients from being trapped in an artificially limited medical market.

Respectfully,

[Your Name]
[City], Louisiana
[Contact Information]